3(R)-[[2-(4-methyl-1-piperazinyl)phenyl]methyl]-1-[4(trifluoromethyl)phenyl]-2-pyrrolidinone | 347867-80-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3(R)-[[2-(4-methyl-1-piperazinyl)phenyl]methyl]-1-[4(trifluoromethyl)phenyl]-2-pyrrolidinone
• 英文别名: (3R)-3-[[2-(4-methylpiperazin-1-yl)phenyl]methyl]-1-[4-(trifluoromethyl)phenyl]pyrrolidin-2-one
• CAS: 347867-80-5
• 化学式: C₂₃H₂₆F₃N₃O
• 分子量: 417.474
• InChiKey: HRIJMEXHEDAGJI-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  26.8
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists
  申请人：——

  公开号：US20010039280A1

  公开（公告）日：2001-11-08

  The present invention relates to optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinones and pharmaceutically acceptable salts thereof, to processes for their preparation, to isotopically-labeled analogs thereof, to pharmaceutical compositions comprising them and to their medicinal use as selective antagonists of the 5-HT 1D receptor. The compounds of the invention are useful in treating depression, obsessive-compulsive disorder (OCD) and diseases, disorders or conditions for which a 5-HT 1D receptor selective antagonist is therapeutically indicated.

  本发明涉及光学活性的3-[(2-哌嗪基苯基)甲基]-1-[4-(三氟甲基)苯基]-2-吡咯烷酮及其药学上可接受的盐，其制备方法，其同位素标记的类似物，包含它们的制药组合物以及它们作为5-HT1D受体选择性拮抗剂的药用用途。本发明的化合物在治疗抑郁症、强迫症(OCD)和需要5-HT1D受体选择性拮抗剂治疗的疾病、疾病或病况中很有用。
• Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists
  申请人：——

  公开号：US20030083337A1

  公开（公告）日：2003-05-01

  The present invention relates to optically active 3-[(2-piperazinylphenyl)methyl]-1-[4(trifluoromethylphenyl]-2-pyrrolidinones and pharmaceutically acceptable salts thereof, to processes for their preparation, to isotopically-labeled analogs thereof, to pharmaceutical compositions comprising them and to their medicinal use as selective antagonists of the 5-HT 1D rector. The compounds of the invention are useful in treating depression, obsessive-compulsive disorder (OCD) and diseases, disorders or conditions for which a 5-HT 1D receptor selective antagonist is therapeutically indicated.

  本发明涉及光学活性的3-[(2-哌嗪基苯基)甲基]-1-[4-(三氟甲基苯基)]-2-吡咯烷酮及其药学上可接受的盐，以及它们的制备过程、同位素标记的类似物、包含它们的制药组合物和它们作为5-HT1D受体选择性拮抗剂的药用用途。本发明的化合物在治疗抑郁症、强迫症和需要5-HT1D受体选择性拮抗剂治疗的疾病，紊乱或情况中有用。
• Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists
  申请人：Pfizer Products Inc.

  公开号：EP1113015A1

  公开（公告）日：2001-07-04

  The present invention relates to optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinones and pharmaceutically acceptable salts thereof, to processes for their preparation, to isotopically-labeled analogs thereof, to pharmaceutical compositions comprising them and to their medicinal use as selective antagonists of the 5-HTID receptor. The compounds of the invention are useful in treating depression, obsessive-compulsive disorder (OCD) and diseases, disorders or conditions for which a 5-HTID receptor selective antagonist is therapeutically indicated.

  本发明涉及光学活性3-[(2-哌嗪基苯基)甲基]-1-[4-(三氟甲基)苯基]-2-吡咯烷酮及其药学上可接受的盐、其制备工艺、其同位素标记类似物、包含它们的药物组合物以及它们作为5-HTID受体选择性拮抗剂的药用用途。本发明的化合物可用于治疗抑郁症、强迫症（OCD）以及5-HTID受体选择性拮抗剂可用于治疗的疾病、失调或病症。
• Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists
  申请人：Howard Ralph Harry

  公开号：US20050182049A1

  公开（公告）日：2005-08-18

  The present invention relates to a pharmaceutical composition for treating a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar atazia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) a γ-aminobutyric acid modulator or a pharmaceutically acceptable salt thereof, (ii) a 5-HT 1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT 1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.

  本发明涉及一种药物组合物，用于治疗选自由高血压、抑郁症、广泛性焦虑症、恐惧症、创伤后应激障碍、回避型人格障碍、性功能障碍、进食障碍、肥胖症、化学依赖性、丛集性头痛、偏头痛、疼痛、阿尔茨海默病、强迫症、惊恐障碍、记忆障碍、帕金森病、内分泌失调症、小脑躁狂症、胃肠道疾病、精神分裂症的阴性症状、经前期综合征、纤维肌痛、帕金森病、内分泌失调、小脑萎缩、胃肠道失调、精神分裂症的阴性症状、经前期综合征、纤维肌痛综合征、压力性尿失禁、抽动秽语综合征、秽语综合征、盗窃癖、男性阳痿、癌症、慢性阵发性头痛和哺乳动物（最好是人类）的头痛，包括 (i) γ-氨基丁酸调节剂或其药学上可接受的盐、 (ii) 5-HT 1B 受体拮抗剂或其药学上可接受的盐、 其中 5-HT 1B 受体拮抗剂选自由以下组成的组 (A) 如说明书所述的式 I 化合物和 (B) 如说明书所述的式 II 化合物，以及 (iii) 可选的药学上可接受的载体。
• Combination of atypical antipsychotics and 5HT-1B receptor antagonists
  申请人：Brodney A. Michael

  公开号：US20050256112A1

  公开（公告）日：2005-11-17

  The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT 1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT 1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.

  本发明涉及一种药物组合物，用于治疗例如选自以下组别的疾病或病症：高血压、抑郁症、广泛性焦虑症、恐惧症、创伤后应激障碍、回避型人格障碍、性功能障碍、饮食失调、肥胖症、化学依赖、丛集性头痛、偏头痛、疼痛、阿尔茨海默病、强迫症、惊恐障碍、记忆障碍、帕金森病、内分泌失调、小脑共济失调、胃肠道疾病、精神分裂症的阴性症状、经前期综合征、纤维肌痛、在哺乳动物（最好是人类）中用于治疗记忆障碍、帕金森病、内分泌失调、小脑共济失调、胃肠道疾病、精神分裂症的阴性症状、经前期综合征、纤维肌痛综合征、压力性尿失禁、抽动秽语综合征、毛细血管扩张症、盗窃癖、男性阳痿、癌症、慢性阵发性颅内出血和头痛，包括 (i) 非典型抗精神病药或其药学上可接受的盐、 (ii) 一种 5-HT 1B 受体拮抗剂或其药学上可接受的盐，其中 5-HT 1B 受体拮抗剂选自(A)本说明书所述的式 I 化合物和(B)本说明书所述的式 II 化合物组成的组，以及可选的(iii)药学上可接受的载体。